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sclerosis discovered by meta-analysis informed by genetic
correlations
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Helgi Valdimarsson11,12, Sigurdur Bjornsson7,15, Unnur S. Bjornsdottir7, Einar S Bjornsson7,12, Bjorn Nilsson29, Ole A. Andreassen 30,
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A meta-analysis of publicly available summary statistics on multiple sclerosis combined with three Nordic multiple sclerosis cohorts
(21,079 cases, 371,198 controls) revealed seven sequence variants associating with multiple sclerosis, not reported previously. Using
polygenic risk scores based on public summary statistics of variants outside the major histocompatibility complex region we
quantiﬁed genetic overlap between common autoimmune diseases in Icelanders and identiﬁed disease clusters characterized by
autoantibody presence/absence. As multiple sclerosis-polygenic risk scores captures the risk of primary biliary cirrhosis and vice
versa (P = 1.6 × 10−7, 4.3 × 10−9) we used primary biliary cirrhosis as a proxy-phenotype for multiple sclerosis, the idea being that
variants conferring risk of primary biliary cirrhosis have a prior probability of conferring risk of multiple sclerosis. We tested 255
variants forming the primary biliary cirrhosis-polygenic risk score and found seven multiple sclerosis-associating variants not
correlated with any previously established multiple sclerosis variants. Most of the variants discovered are close to or within
immune-related genes. One is a low-frequency missense variant in TYK2, another is a missense variant in MTHFR that reduces the
function of the encoded enzyme affecting methionine metabolism, reported to be dysregulated in multiple sclerosis brain.
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INTRODUCTION
Multiple sclerosis (MS) is a disease in which the oligodendrocytes
and the myelin sheets surrounding the axons in the central
nervous system are destroyed. Although the causes of MS remain
to be determined, it is a widely held opinion that MS is an
autoimmune disease (AD) rather than a degenerative neurological
disease.1 Indeed, genetic studies of MS have yielded more loci
inﬂuencing immunological than neurological processes and
there is a substantial overlap between risk loci for MS and other
ADs.2
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Early genome-wide association studies (GWAS) revealed that
many ADs share susceptibility loci.3 This motivated the develop-
ment of the Immunochip, designed to densely cover immune-
related loci and loci thought to associate with one or more AD.4
Studies using the Immunochip have yielded susceptibility loci for
MS,2 rheumatoid arthritis (RA),5 psoriasis (PSO),6 celiac disease
(Cel),7 type 1 diabetes (T1D),8 juvenile idiopathic arthritis (JIA),9
primary biliary cirrhosis (PBC),10 Crohn’s disease (CD),11 ulcerative
colitis (UC)12 and more. These studies have also revealed
considerable overlap of susceptibility loci for many pairs of ADs
although the sizes and even the directions of effects vary among
diseases.13
Polygenic traits, whose risk is affected by a large number of
susceptibility variants, require large sample sizes for variants to
survive correction for multiple testing in a typical GWAS setting. By
establishing prior probabilities, the burden of multiple testing can
be reduced. The proxy-phenotype method involves establishing a
genetic correlation between two traits and then variants associat-
ing with one phenotype serve as “empirically based candidate
SNPs” for a second phenotype.14 Polygenic risk score (PRS)
analyses of many complex traits have shown that a substantial
genetic signal resides among the variants not achieving sig-
niﬁcance in association studies.15, 16 While restricting to variants
showing a signiﬁcant association with phenotype A when
selecting variants for testing in phenotype B is the approach
taken in the proxy-phenotype method,14 it is logical to extend this
idea to variants that show larger P-values of association, provided
the additional variants capture genetic effect, as shown with the
use of PRSs.
The current study consists of three phases. First, we performed a
meta-analyses of publicly available summary statistics from a large
study of MS2 and three Nordic MS cohorts, identifying seven
variants that had not reached genome-wide signiﬁcance in
previously published GWAS. Second, we used PRSs based on
public summary statistics (downloaded from Immunobase and IBD
Genetics) to quantify the genetic overlap between pairs of ADs in
Iceland that is due to common sequence variation, excluding the
human leukocyte antigen (HLA) region (due to the extended and
complex linkage disequilibrium), ﬁnding–among other things–a
strong genetic relationship between MS and PBC. Third, utilizing
the knowledge of genetic overlap between PBC and MS, we tested
the variants contributing to the most predictive PBC-PRS for
association with MS, and found seven additional variants affecting
risk of MS that have not been previously reported.
RESULTS
Meta-analysis
We performed two inverse variance weighted meta-analyses. In
the ﬁrst, which was meant to maximize statistical power for those
variants found on the immunochip, we combined publicly
available summary statistics from the discovery phase of a large
international study of MS, referred to as the IMSGC study2 (Ncase =
14,498, Nctrl = 24,091), with summary statistics from MS cohorts
from Sweden (Ncase = 4505, Nctrl = 6105), Norway (Ncase = 1013,
Nctrl = 23,363) and Iceland (Ncase = 1063, Nctrl = 317,639) (Supple-
mentary Table 1). This resulted in combined summary statistics for
117,990 single nucleotide polymorphisms (SNPs) that survived
quality control in the IMSGC data and two or more Nordic cohorts.
Being from an Immunochip study, the IMSGC data densely covers
loci thought to contain candidate genes for ADs, and does not
cover the whole genome. The IMSGC cohort further partially
overlaps with our Swedish cohort. To search for variants not
tagged by any variant on the Immunochip, we performed a
second analysis, combining statistics from association testing of
imputed genotypes of the three Nordic cohorts, additionally
including 1670 cases and 1534 controls in the Swedish cohort
that overlapped with the IMSGC study and were therefore
excluded from the ﬁrst analysis. This yielded combined summary
statistics for 6,694,339 SNPs that survived quality control in all
three studies.
Excluding the major histocompatibility complex (MHC) region, a
total of 94 independent variants reached genome-wide signiﬁ-
cance with P < 5 × 10−8 in the ﬁrst analysis and 24 in the second
analysis. Of the newly discovered variants, seven represent signals
not previously reported for MS at genome-wide signiﬁcance level.
Six represented loci not previously associated with the disease in
GWAS (Table 1, Fig. 1, Supplementary Table 2 and Supplementary
Figs. 1–7) while one is a secondary signal at a previously reported
locus.
Only one of our newly discovered MS variants is absent from
the Immunochip. The association of rs1801133 with MS was
uncovered in the combined analysis of the three Nordic sample
sets and is a missense variant is in exon 5 of the MTHFR gene,
encoding 5,10-methylenetetrahydrofolate reductase, a key
enzyme in the intracellular folate (vitamin B9) metabolism and
homeostasis. The T allele causes a change of alanine in position
222 to valine. No other sequence variant has a correlation over
0.56 with this variant in Iceland nor in the European 1000
Genomes data, suggesting that rs1801133 itself is causative. This
Table 1. Meta-analyses identify seven novel risk variants associating with multiple sclerosis
Chr Positiona rsID MA OA MAF [%] P-value OR (95% CI) Closest gene(s) Annotation
1 11796321 rs1801133b T C 34.4 6.9 × 10−9 0.88 (0.84, 0.92) MTHFR Missense
1 198808343 rs9427431 C T 39.4 2.2 × 10−8 0.93 (0.91, 0.95) MIR181A1HG,MIR181B1,MIR181A1,
PTPRC,LINC01222,LINC01221
Intergenic
3 188370473 rs11707807 G A 41.5 1.2 × 10−8 1.08 (1.05, 1.11) LPP Intronic
8 70306125 rs13260060 A G 8.5 2.5 × 10−8 1.12 (1.08, 1.17) NCOA2 Intronic
11 61066152 rs175126c G A 45.5 3.3 × 10−12 1.10 (1.07, 1.13) CD6, CD5 Intergenic
11 128551691 rs4245080 A G 47.2 1.5 × 10−8 1.09 (1.06, 1.12) ETS1 Intronic
13 50267187 rs806321 C T 46.1 5.1 × 10−10 0.92 (0.90, 0.94) DLEU1,ST13P4,DLEU2,MIR15A,
MIR16-1,KCNRG
Intergenic
OR is the OR of the minor allele
Chr chromosome number, MA minor allele in Iceland, OA other allele, MAF minor allele frequency in Iceland, CI conﬁdence interval
a Build hg38
b Variant not included in the IMSGC study
c After conditioning on rs34383631, previously reported to associate with MS2
Sequence variants associated with MS
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Fig. 1 Forest plot for variants discovered in a meta-analysis of MS cohorts. a rs11707807; b rs9427431; c rs13260060; d rs4245080; e rs175126; f
rs1801133; g rs806321
Sequence variants associated with MS
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particular mutation has been studied in the context of cardiovas-
cular disease and is known to disrupt the function of 5,10-
methylenetetrahydrofolate reductase so that rs1801133(T;C)
heterozygotes have 35% less function and rs1801133(T;T) homo-
zygotes have 70% less function of the enzyme than rs1801133(C;
C) homozygotes, resulting in increased homocysteine levels in
blood.17 The minor allele (A) of another variant in MTHFR,
rs1801131, causes change of glutamate in position 429 to alanine.
rs1801131 has also been associated with decreased function of
the enzyme but to a lesser degree than rs1801133 and does not
associate with the risk of MS in our material (P = 0.46, OR = 0.98).
All other variants identiﬁed in this phase of the study are
intergenic or intronic and none correlate with coding or splice site
variants in the Icelandic material (Supplementary Table 3). While
rs9427431 and rs175126 are close to genes encoding proteins with
roles to play in T-cell adhesion and activation the remaining four
variants lie within or close to genes that function as regulators of
transcription. In an attempt to understand the mechanism and
assess the consequences of all the sequence variants, we explored
their effects on expression by looking them up in the Genotype
Tissue Expression (GTEx) project18 and in data from a large Icelandic
study of expression quantitative trait loci (eQTLs) in whole blood,19
only linking the associated variant with changes in expression when
it is either itself the variant most strongly associated with expression
in the locus, or highly correlated (r2 > 0.94 in deCODE data) with that
variant. We also determined whether the variants had previously
been reported to associate with any AD and if they belonged to
potential transcription factor binding sites (TFBS) in the ORegAnno
database20 or likely enhancer elements as deﬁned by histone
modiﬁcation patterns in the ENCODE project.21 Lastly, we explored
variants correlated with our reported variant in Iceland to search for
possible coding or splice site variants that might not have been
included on the Immunochip (Supplementary Table 3). The newly
identiﬁed variants are listed and further discussed in the supple-
mentary note accompanying the paper.
PRS analysis
Risk alleles, P-values and effect estimates were extracted from
publicly available summary statistics from ten studies of ADs
(Supplementary Table 4) and used to deﬁne PRSs that were then
calculated for 150,656 Icelanders. We excluded the extended MHC
region (chr6:25000000–35000000, build hg38) from this analysis
because of the number of strong associations with ADs and the
complex linkage disequilibrium structure of the region. The
association of the AD-PRS was tested with its corresponding
disease in Iceland (Supplementary Table 5) at 10 P-value inclusion
thresholds, and the threshold at which the largest part of the
variance in case-control status of Icelanders was explained by the
score was identiﬁed (Fig. 2 and Supplementary Tables 6 and 7).
For eight ADs, the most predictive score was calibrated so that a
unit increase in PRS dictated a doubling of risk of the
corresponding disease (Online methods). Icelandic cohorts were
not available for JIA and Cel so the scores were normalized to have
a mean of zero and a standard deviation of one and a P-value
threshold of 0.001 was arbitrarily selected. Next, we tested each
PRS for association with nine other ADs and asthma, as an
example of a non-autoimmune inﬂammatory disease. We found
that ADs can be genetically divided into clusters of seronegative
ADs (CD, UC, PSO and ankylosing spondylitis (AS)), in which
autoantibodies are rarely seen, and seropositive ADs (JIA, RA, Cel,
T1D, autoimmune thyroiditis (AITD) and systemic lupus erythe-
matosus (SLE)), where autoantibodies are commonly found or
represent characteristic features. Most diseases within each cluster
show evidence of correlation but associations across the
serological divide are rare (Fig. 3, Supplementary Table 8). Broadly
speaking, this is the same trend as has been observed when
comparing ADs on the basis of established risk loci.13
Interestingly, PBC and MS could not be placed in either cluster.
The PBC-PRS associates with several diseases, both classiﬁed as
seronegative and seropositive, while the MS-PRS only correlates
strongly with PBC (Fig. 3). PBC-PRS corresponding to doubling
in risk of PBC increased risk of MS by 29% (P = 4.3 × 10−9) and
Fig. 2 The variance explained by PRS for training diseases predicting the corresponding disease in the Icelandic target cohorts. These bars
show how much variance of the phenotype is explained at a given P-value threshold by the PRS calculated from the training set for the same
phenotype. Celiac disease (Cel) and juvenile idiopathic arthritis (JIA) are not included in the ﬁgure as no Icelandic cohorts were available for
these diseases. For JIA and Cel, a P-value inclusion of 0.001 was arbitrarily selected. MS multiple sclerosis; PBC primary biliary cirrhosis; T1D type
1 diabetes; CD Crohn’s disease; UC ulcerative colitis; RA rheumatoid arthritis; PSO psoriasis; SLE systemic lupus erythematosus
Sequence variants associated with MS
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MS-PRS corresponding to doubling in risk of MS increased risk of
PBC by 81% (P = 1.56 × 10−7). We also found that T1D-PRS more
modestly associates with risk of MS but not vice versa. Several
PRSs associated with PBC status, despite very modest size of this
sample set, but no other PRSs than those for PBC and T1D
associate with MS. We replicated these ﬁndings in the Swedish MS
cohort (Table 2). We also explored the association of the PRSs with
levels of disability, measured with the multiple sclerosis severity
score (MSSS)22 in a subset of 5173 Swedish MS patients for which
MSSS data were available (within the subset of samples that didn’t
overlap with the IMSGC study, in the case of MS-PRS). Despite
large sample size we observed no signiﬁcant associations after
correcting for multiple tests (Table 2), suggesting that MS severity
is largely determined by factors other than those conferring
genetic susceptibility to disease onset.
We note that the public data sets we used to derive the PRSs
are based on the Immunochip, whose variants were selected to be
more likely to associate with ADs than random variants, because
these data sets represent the largest (or only) studies of these
diseases for which summary statistics are available. Where
possible, we repeated our analysis using studies covering the
whole genome (excluding the MHC region) and obtained
comparable results (Supplementary Tables 9–12).
Proxy-phenotype analysis
Having established a strong genetic relationship between MS and
PBC, we decided to use PBC as a proxy for MS. Out of 263 variants
contributing to the PBC-PRS, 255 survived quality control in three
or more MS data sets and 49 associate with MS after correction for
multiple testing (P = 2 × 10−4). Out of the 49 signiﬁcant variants 46
have concordant effects on MS and PBC (Supplementary Fig. 8).
One of the discordant variants, rs10797431 at the MMEL1 locus,
has previously been reported to be genome-wide signiﬁcant, both
conferring risk of PBC23 and protection against MS.2 It has been
shown that for ADs the most associated variant at a given locus
frequently differs between the diseases and, even when shared,
the same allele often has opposite effect.13 We excluded the
variants with discordant effect from further analysis.
Out of the 46 remaining variants signiﬁcantly associating with
MS seven represent signals that are not explained by any of the
108 established MS variants (Table 3, Fig. 4, Supplementary
Table 13 and Supplementary Figs. 9–15). rs35018800-A is a
missense variant in tyrosine kinase 2 (TYK2), which causes a
change of alanine to valine in position 928. This change, which has
previously been reported to protect against RA and SLE,24 also
protects against MS and is independent of the effect of another
missense variant in TYK2, rs34536443-C, which has been shown to
protect against MS.25
Many of the variants identiﬁed in the proxy-phenotype analysis
may confer their risk through effects on interleukin signaling
pathways. In addition to the missense variant in TYK2, rs17674224
is located in an intron of TXK, a gene that encodes another
member of the tyrosine kinase family. TXK is a Th1-speciﬁc
transcription factor and regulates the production of IFNg and
other cytokines produced by these cells,26 important for
speciﬁcation and activation of various immune cells.
We also found that the G-allele of rs72678531, in an intron of
IL12RB2, is associated with increased risk of MS. The encoded protein
forms a subunit of IL-12 receptor, which upon binding of the
cytokine IL-12 initiates an intracellular signaling cascade, involving
several members of the tyrosine kinase family of proteins, ultimately
leading to differentiation of naive T-cells into Th1 cells.27 The gene
encoding the other subunit of the receptor, IL12RB1, has already
Fig. 3 A heat map showing the genetic relationships between
autoimmune diseases and asthma. Squares labeled with an asterisk
are signiﬁcant after correcting for 102 tests. The risk ratio where P<
0.05 is plotted so as not to obscure suggestive results but results
with P> 0.05 are omitted for clarity. Squares of dashed lines indicate
clusters of seronegative diseases (upper left) and seropositive (lower
right). Diseases for which polygenic risk scores were calculated are
listed horizontally while diseases for which an Icelandic cohort was
available are listed vertically. AS Ankylosing spondylitis; UC ulcerative
colitis; CD Crohn’s disease; PSO psoriasis; MS multiple sclerosis; PBC,
primary biliary cirrhosis; RA rheumatoid arthritis; SLE, systemic lupus
erythematosus; T1D type 1 diabetes mellitus; Cel celiac disease; JIA
juvenile idiopathic arthritis
Table 2. Replication of primary biliary cirrhosis (PBC) and type 1 diabetes (T1D) polygenic risk score (PRS) prediction of multiple sclerosis (MS) in an
independent Swedish cohort and results for the association of those PRSs and MS-PRS with the multiple sclerosis severity score (MSSS) after
correcting for duration of disease
MS-PRS PBC-PRS T1D-PRS
MS status RR= 2.09 (1.98–2.20) RR= 1.25 (1.21–1.29) RR= 1.06 (1.02–1.10)
P= 1.5 × 10−165 P= 3.1 × 10−40 P= 1.9 × 10−3
MSSS β= 0.03(−0.01,0.07) MSSS units* β= 0.03(−0.00,0.05) MSSS units β= 0.03(0.00,0.06) MSSS units
P= 0.11 P= 0.09 P= 0.04
Brackets enclose 95% conﬁdence intervals for risk ratio estimates
RR risk ratio
*The MS PRS was tested for association with MS status and MSSS after excluding samples that overlapped with the IMSGC study (see text)
Sequence variants associated with MS
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been shown to associate with MS.2 We found that the G-allele
rs72678531 is associated with increased expression of IL12RB2 in
whole blood (5.2% increase, P = 7.0 × 10−15) in the deCODE eQTL
data set and in the GTEx data (β = 0.37 SD, P = 7.1 × 10−13). Finally
rs35188261 is located in an intron of TNPO3 close to IRF5, previously
shown to associate with MS in a candidate gene study28 but has not
reached signiﬁcance in GWAS. The variant we report for this locus,
rs35188261, shows low correlation (r2 = 0.13) with the top variant
from the candidate gene study of Kristjansdottir et al (rs4728142),
and may represent a secondary signal in the locus if rs4728142
proves to be a true association. rs4728142 is not included in the
PBC-PRS and came short of reaching genome-wide signiﬁcance in
the meta-analysis (P = 6.4 × 10−7). IRF5 regulates the transcription of
type 1 interferon and other cytokines, including IL12.29 The beta
interferons were the ﬁrst disease-modifying therapies approved for
MS, inﬂuencing the immune system at many levels, resulting in
sustained anti-inﬂammatory state.30 We again refer to the supple-
mentary note for discussion of all the newly identiﬁed variants.
DISCUSSION
We have discovered 14 variants not previously reported to
associate with MS in GWAS. Seven of the variants were identiﬁed
based on their association with PBC, the AD showing the strongest
genetic relationship with MS (Table 3). Other than rs175126 in the
CD6, CD5 locus and rs35018800 in the TYK2 locus, these variants
are within loci not previously associated with MS. rs806321 and
rs12871645 are two independent signals in the same novel locus.
Most of the variants are within or close to immunologically relevant
genes and many have previously been associated with other ADs
(Supplementary note). Although only one variant could be directly
associated with changes in transcription of close genes in whole
blood, several of the variants are in regions that overlap with
known binding sites for transcription factors and/or have histone
modiﬁcation proﬁles suggestive of possible enhancer function in
GM cells from ENCODE (Supplementary note). We have postulated
functional effects for these variants but further investigation is
needed to establish their role in the pathogenesis of MS. The newly
discovered variants explain 4.3% of the phenotypic variance in MS
in Iceland compared to 22.9% explained by previously associated
variants and 12.6% explained by HLA alleles showing additive
association with disease in a recent publication.31 This estimate is
conservative as it does not include dominant effects or gene–gene
interactions identiﬁed in the region.
Two missense variants, both protecting against MS, were
discovered in this study. The T-allele of rs1801133 (A222V
missense) in MTHFR is known to increase the level of homo-
cysteine in blood. The product of MTHFR, 5,10-methylenetetrahy-
drofolate reductase, catalyzes the conversion of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-
substrate for vitamin B12-dependent homocysteine re-
methylation to methionine. Vitamin B12 deﬁciency and MS share
pathological changes and B12-dependent methylation and
MTHFR have been suspected to play a role in MS for decades.32
Homocysteine levels in the blood and cerebrospinal ﬂuid of MS
patients have been found to be elevated in some studies,33–35 but
not in others.36, 37 A recent study found different concentrations
of methionine metabolites in brains of MS patients compared to
brains of controls and suggested an effect on mitochondria and
neuronal energetics.38
The variant rs35018800-A is a low-frequency (MAF = 1.4%,
0.77% and 0.97% in Iceland, Norway and Sweden, respectively)
missense variant in TYK2 and has the largest effect on MS risk of
any variant outside the MHC region discovered to date. It is not
clear what the effect of the amino acid substitution is on the
function of the protein.
In the proxy-phenotype step, we observed strong enrichment
and concordance of effect for PBC variants associating with MST
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Fig. 4 Forest plots for MS variants discovered through the proxy-phenotype method. a rs72678531; b rs17674224; c rs35188261;
d rs12871645; e rs2271293; f rs35018800; g rs2073167
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(Supplementary Fig. 8). This is in agreement with 9.1% of the
variants reported in the most recent IMSGC GWAS overlapping
with PBC signals.2 However, the observed enrichment is likely to
be also partially explained by the overlap in controls between the
Immunochip studies of PBC and MS (Online methods). In the
proxy-phenotype analysis, the best independent sequence variant
for PBC in a region was selected and tested for association with
MS. It is important to note that the best variant for PBC at a locus
may not necessarily be the variant most strongly associated with
MS (Supplementary Figs. 9 and 10). The same variant might be
responsible for the signal observed in both studies but sampling
noise determines precisely which variant in an linkage disequili-
brium (LD) block tests most signiﬁcant. As the IMSGC data include
relatively few markers, it is also probable that neither of the top
variants is the true causal variant responsible for the signal at the
locus. We note that as the suggestive PBC variants associate
signiﬁcantly with MS, it seems probable that they truly associate
with PBC as well. It is also important to note that although we
applied genomic control (GC) to each of the Nordic cohorts, the
IMSGC summary statistics have not been GC corrected, which may
cause some inﬂation of test statistics. These variants survive
correction for the number of tests performed. However, they do
not reach the arbitrary but commonly used deﬁnition of genome-
wide signiﬁcance and some caution in their interpretation is
warranted until they have been replicated by the scientiﬁc
community.
We have used individual genotype data on a population level to
comprehensively map genetic overlap between the most
common ADs within a single population. We add to existing
evidence of the polygenic architecture of these diseases and show
that there is extensive genetic overlap between many pairs of ADs.
In particular, we have established a strong genetic relationship
between MS and PBC, and a less signiﬁcant relationship between
MS and T1D. A great number of the SNPs in and between genes so
far associated with a variety of diseases are pleiotropic39, 40 and
much work has been done to quantify the genetic overlap
between traits.41, 42 This study establishes genetic relationships
between many pairs of ADs and demonstrates how knowledge of
genetic relationship can be used to establish priors and thereby to
increase power of association studies, allowing for the identiﬁca-
tion of the speciﬁc pleiotropic loci responsible for the overlap. The
sequence variants identiﬁed in this study explain a modest
fraction of the phenotypic variance in MS but will hopefully help
to identify biological pathways contributing to the disease.
Supplementary information is available at Genomic medicine’s
website.
METHODS
All methods were performed in accordance with relevant guidelines and
regulations.
Subject recruitment
Icelandic samples used were obtained through ongoing deCODE studies of
Icelanders. They were approved by the National Bioethics Committee
(permit numbers: MS-VSN_15-212, RA-VSN_15-045, IBD-VSN_98-059, AS-
VSN_98-020, PSO-VSN_14-118, T1D-VSN_12-156, AITD, SLE and PBC-
VSN_08-059, Asthma-VSN-14-099) and the Icelandic Data Protection
Authority. All patients and controls who donated DNA samples signed
informed consent. Personal identiﬁers of the patient data and biological
samples were encrypted by a third party system approved and monitored
by the Data Protection Authority.
The Icelandic MS cohort consisted of patients diagnosed from
1950–2005 and followed-up at Landspitali, the National University Hospital
of Iceland, or an outpatient department for MS patients in Reykjavik,
Iceland.43 The RA patients were diagnosed in 1942–2010 at Landspitali, at
the Centre for rheumatology research or at a private clinic in Reykjavik.44
RA was deﬁned according to the 1987 revised criteria of the American
college of rheumatology (ACR).45 All patients met four or more of the ACR
criteria. Inﬂammatory bowel disease (IBD) patients consisted of all patients
diagnosed with UC or CD by a gastroenterologist in Iceland 1950–2013.
The diagnoses of all IBD patients were reviewed independently and
fulﬁlled accepted diagnostic criteria, and all have had at least 1 year of
follow-up evaluation and many patients have had decades of re-evaluation
and conﬁrmation of their ﬁnal diagnosis.46, 47 The AS cohort consisted of all
known AS patients in Iceland in 2010.48 All patients were interviewed and
examined by a rheumatologist and found to fulﬁll the modiﬁed New York
classiﬁcation criteria for AS.49 PSO patients were diagnosed by dermatol-
ogists at Reykjavik dermatology clinic (1991–2014) or recruited through
the Icelandic psoriasis association (SPOEX). A detailed clinical history was
obtained by a structured questionnaire, and a careful physical examination
was also carried out and the localization, distribution, and the size of the
lesions were recorded.50 The T1D patients are all diagnosed with T1D and
admitted to the national pediatric diabetes centre at Landspitali, for
treatment and follow up until 2009.51 The AITD cohort consisted of all
patients diagnosed with Grave’s disease or Hashimoto’s thyroiditis
according to the ICD10 codes and ICD9 codes at Landspitali until 2010.
Patients with systemic lupus erythomatosus (SLE) are all SLE patients
diagnosed at the Landspitali, Centre for rheumatology research or at a
private clinic of Reykjavik until 2011,52 who met at least four of the ACR
criteria for the classiﬁcation of SLE.53 Patients with PBC were identiﬁed at
Landspitali by presence of anti-mitochondrial antibodies, ICD9 and ICD10
codes and pathological registries and the National death registry from
1991 to 2010.54
Asthma patients, 18–45 years of age, who visited an asthma clinic or
emergency room at the National University Hospital of Iceland or the
Icelandic Medical Centre (Laeknasetrid) during the years 1977–2014,
received the ICD diagnosis or responded positively to the question: “Has a
doctor conﬁrmed your asthma diagnosis?” were included.55
The summary characteristics of the AD and asthma sample sets are
available in Supplementary Table 5.
The Swedish MS cases and all but 2387 of the controls represent an
extended collection of subjects from two population based case-control
studies in Sweden, the Epidemiological investigation of multiple Sclerosis
study and the Genes and environment in multiple Sclerosis study.56 All
patients were diagnosed according to the McDonald criteria.57 Controls
were randomly chosen from population registers and matched with cases
by sex, age, and region of residence. The remaining 2387 controls are
Swedish blood donors that were randomly ascertained from Skåne county
in southern Sweden. Sample collection took place during summer and
autumn of 2014. All samples were collected subject to ethical approval
(Lund University ethical review board; dnr 2013/54).
The Norwegian MS cohort consists of 1013 MS patients recruited from
the Oslo MS clinic and Norwegian MS biobank and registry. All patients
were diagnosed according to the McDonald criteria.57 The MS biobank and
registry also provided 30 controls. A further 23,333 controls come from
three studies of Norwegians: 4856 samples constituted an extended set of
Alzheimer’s and dementia subjects described previously,58 6550 samples
were recruited as a part of the Norwegian mother and child cohort study
(MoBa),59 which includes more than 114,000 children, 95,000 mothers and
75,000 fathers. Pregnant women attending a routine ultrasound examina-
tion were initially invited. The ﬁrst child was born in October 1999 and the
last in July 2009. Further information can be found at [www.fhi.no/moba-
en]. Finally 11,927 subjects come from the thematically organized
psychosis research study. Subjects between ages 18–65 were recruited
from psychiatric departments and outpatient clinics in Oslo. All studies
were approved by the regional ethics committee and the Norwegian
authorities for collection of medical data, and written informed consent
was obtained from all participants.
Genotyping, imputation and association analysis
Icelandic samples were genotyped on Illumina HumanHap300,
HumanCNV30, HumanHap610, HumanHap1M, HumanHap660, Omni-1,
Omni2.5 or Omni Express bead chips at deCODE Genetics. Prior to
imputation, samples with <97% call rate were excluded as well as all SNPs
with genotyping yield <95% or MAF < 1%. Some samples were genotyped
on more than one chip and in those cases, all SNPs with substantial
difference in call rate between chip types were excluded. Further, all SNPs
showing P < 0.001 for deviation from Hardy–Weinberg equilibrium or a >
0.1% inheritance error rate were removed. Subjects were long range-
phased and imputation into both chip-typed individuals and their close
relatives was based on a panel of 8453 whole genome sequenced
Icelanders.60 This process has been described in greater detail
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elsewhere.60–62 Brieﬂy, regions of identity by descent are identiﬁed and
used to phase haplotypes with great certainty. Making use of genealogy
information, it is possible to deduce haplotypes for individuals that have
not been genotyped, provided some of their relatives have been
genotyped. Association testing was performed using logistic regression,
adjusting for age and county of birth.
Genotyping of the Swedish cohort was carried out at deCODE using
Illumina Omni chips. Phasing was performed using SHAPEIT2,63, 64 and
imputation was carried out using IMPUTE265, 66 based on the 1000
Genomes phase I integrated haplotypes generated using SHAPEIT2.67 Prior
to imputation, SNPs having yield <95%, Hardy–Weinberg equilibrium P-
values <1 × 10−5, or either A/T or G/C allele combinations were removed.
Samples having <95% genotyping yield or evidence of non-European
ancestry based on results from Structure using European (CEU), Chinese
and Japanese (CHB + JPT) and Nigerian (YRI) individuals from the HapMap
project as reference samples, as well as one of each pair of duplicate
samples were also excluded. Association analysis was carried out using
SNPTEST268 with 20 principal components included as covariates. Principal
components were calculated using EIGENSOFT.69
Genotyping of the Norwegian controls was carried out at deCODE using
the Omni series of Illumina bead chips but Norwegian cases were
genotyped on Human660-Quad at the Sanger institute in a collaboration
with the International MS genetics consortium and the Wellcome Trust
case control consortium.70 Samples were phased and imputed together
based on the SNPs found on both chip types using the same methods and
quality control as for the Swedish cohort. Association analysis was carried
out using SNPTEST268 with ten principal components included as
covariates.
Meta-analysis
We carried out an inverse-variance weighted meta-analysis under the
assumption of ﬁxed effect using the METAL software71 in two steps. First,
we combined publicly available summary statistics from the largest study
of MS to date, referred to as the IMSGC study, with summary statistics from
our three Nordic cohorts. This resulted in combined statistics for 117,990
SNPs, which survived quality control in the IMSGC data and two or more of
the Nordic cohorts. In the second step, we included in the Swedish cohort
1670 cases and 1534 controls that were excluded from the ﬁrst analysis on
the basis of overlap with the IMSGC study. Imputation and principal
component calculations were repeated for the Swedish cohort after
adding these samples. This resulted in combined summary statistics for
6,694,339 SNPs that survived quality control in all three Nordic cohorts.
Conditional analysis of the IMSGC data was performed using GCTA72 and
the genotypes of 6500 randomly selected Icelanders as LD reference.
For some of the candidate markers, for example in the case of rs175126,
the adjusted P-value was reported in Supplementary table 2 of the IMSGC
paper.2 Where this information was available, we used the P-value
provided by the IMSGC as that more accurately reﬂects the LD structure of
all the study cohorts. Locus plots were generated using LocusZoom,73
displaying only variants surviving quality control in all cohorts (all Nordic
cohorts only for rs1801133) and unconditioned P-values.
Target and training sets for PRSs analyses
For PRS calculations, two types of data sets are required. The ﬁrst, referred
to as training set, comprises summary statistics from an external GWAS or a
meta-analysis. The second, referred to as target set, consists of genotypes
and phenotypes for a cohort that is independent of the training set cohort.
For use as training sets, summary statistics from the discovery phase of
many of the largest association studies of ADs to date were downloaded
from http://www.immunobase.org/ (accessed 10.11.2015 by S.J.) and from
https://www.ibdgenetics.org/downloads.html (accessed in January 2017 by
S.O). Many of these studies have employed the Immunochip (an Illumina
Inﬁnum microarray) developed by the Immunochip consortium, to densely
cover loci previously implicated in ADs.4, 13 For consistency, when only
summary statistics from studies covering the whole genome were
available, we extracted the SNPs found on the Immunochip and used
only those SNPs for calculating the PRS. We later validated our ﬁndings
using summary statistics from studies covering the whole genome.
From all training data sets, we drew the effect allele, the effect estimate
and the P-value of the effect estimate and used those to calculate PRSs as
described below. An overview of the respective studies is provided in
Supplementary Table 3.
A sample of 150,656 genotyped Icelanders, representing more than half
the Icelandic adult population, served as a target set. Subjects were drawn
based on the following criteria:
1. Start with the genotypes of all 150,656 genotyped Icelanders.
2. Identify the age range of cases for each disease and include in the
control group only people who fall within this age range.
3. Remove individuals who harbor long-range phased haplotypes found
not to belong to the set of Icelandic haplotypes.
4. Remove individuals who have less than 98% probability of being of
European ancestry based on results from Structure using genotypes for
2766 ethnicity-sensitive SNPs common to all Illumina SNP arrays and
the HapMap CEU, CHB + JPT and YRI individuals as reference samples.74
For replication and for testing the association of PRSs with multiple
sclerosis status scale (MSSS) we used the Swedish cohort previously
described, excluding the blood bank donors from Skåne, which were
added late to the study.
Polygenic risk scores
PRSs were calculated based on the summary statistics of the training sets
previously listed (Supplementary Table 4), excluding the extended MHC
region (25–35Mb of chromosome 6, build hg38) to ensure no variants in
LD with the MHC region were included in the score.16 Markers found in the
training data were matched with a set of in-house SNPs and only
autosomal, biallelic SNPs with MAF > 1% and info > 0.9 in Iceland were
included. We furthermore excluded AT/GC SNPs to avoid strand matching
issues.
As variants within the MHC region show very strong association with all
the diseases studied here, the exclusion of the MHC might be a source of
controversy. However, its exclusion is critical to the study. PRSs can be used
to establish biological pleiotropy by testing a score composed of a set of
genetic variants contributing to the risk of a given trait for association with
another. In this way, genetic overlap between traits can be detected, even
in the absence of signiﬁcantly associating signals.42 An underlying
assumption is that the effect of a variant represents the effect of a single
biological process common to both traits and variants are pruned so that
only the variant showing the strongest evidence of association within a LD
block is retained. However, due to extensive LD within the MHC region, the
effect of a variant within that region is likely to be composed of the
combined effect of several different genes on the disease. Some of these
genes might contribute to both diseases while others will not. Excluding
the MHC is therefore critical for avoiding the detection of spurious
pleiotropy.
PLINK 1.975 was used to prune SNPs in a sliding window of 500 kb,
retaining the SNP which showed the strongest evidence of association
with the phenotype in the training data and removed SNPs having r2 > 0.1
with that SNP. A set of 960 whole genome sequenced Icelanders, unrelated
at six meioses served as LD reference.60
We calculated a polygenic score for each individual, j, in the target data
at ten different P-value inclusion thresholds using the formula
PRSj ¼
X
i2S βi ´Gj ; (1)
where S is the set of SNPs retained after pruning that have P-values below
the inclusion threshold, β is the effect and Gj is the sum of the probability
of the effect allele being found on either of individual’s j chromosomes.
The pipeline used for calculating the PRS shares many features with the
PRSice software.76
Each PRS, except those calculated for JIA and Cel, was tested for
association with its corresponding disease in Iceland using generalized
additive regression with smoothed age, sex and the ﬁrst ﬁve principal
components as covariates. The best P-value inclusion threshold was
identiﬁed for each disease and the score at this threshold was calibrated so
that a unit increase in the score represented a doubling in risk of its
corresponding phenotype. This can be written as follows:
PRS′ ¼ PRS ´ βPRS
log 2ð Þ ; (2)
where PRS and PRS′ are the uncalibrated and calibrated polygenic risk
scores, respectively, and βPRS represents the log odds of the disease
corresponding to the score in a logistic regression.
The calibrated score was then tested for association with disease status
in each of the other target cohorts, using the same model as described
above. Models were compared against null models that consisted of the
covariates only and results were considered signiﬁcant if P < 5.0 × 10−4.
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For JIA and Cel, PRS were normalized to have a mean of 0 and a
standard deviation of 1 in our sample of 150,656 Icelanders. As the most
predictive threshold could not be determined, we arbitrarily selected the P-
value inclusion threshold 0.001 and tested those scores for association
with disease status in the same manner as described above. The un-
calibrated PRSs were always normally distributed in the population and
remained normally distributed after calibration and the use of these
models is therefore justiﬁed. The ratio of the variance in PRS between cases
and controls never exceeded 1.13 for case-lists with >500 cases and never
exceeded 1.43 for case-lists with <500 cases.
Population stratiﬁcation was estimated by randomly selecting 10,000
variants with minor allele frequency >5% from all over the genome and
testing them for association with disease in each of the target cohorts. We
calculated genomic inﬂation factor λ for the target phenotype in Iceland
and adjusted the P-values of PRS-disease association accordingly.
Nagelkerke’s pseudo-R2 was used as a measure of the variance explained.
We tested the PRSs for MS, PBC and T1D for association with the MSSS
using generalized additive regression with smoothed year of birth, gender
and the ﬁrst 20 principal components as covariates. The PRSs were
standardized so that a unit increase corresponded to doubling in risk of
the respective disease in Iceland. MSSS data were available for 5173
Swedish cases, 1466 of which overlapped with the IMSGC study. When
testing the PBC-PRS and T1D-PRS for association with MSSS, all subjects
were included but the overlapping samples were excluded before testing
the association of the MS-PRS with MSSS.
Proxy phenotype analysis
We extracted from the combined summary statistics from the meta-
analysis 255 SNPs that contributed to the PRS for PBC and survived quality
control in three or more MS data sets. Of those, all four study cohorts
contributed to the statistics for 221 SNP. For these variants, a signiﬁcance
threshold of 2:0 ´ 104 ¼ 0:05255 was applied. It is important to note that
there was some sample overlap between the PBC study used to construct
the PRS and the IMSGC discovery phase included in the meta-analysis. Out
of 24,091 controls used in the IMSGC study, 4422 came from three sites
within the United Kingdom, two of which also provided controls to the PBC
study of Liu et al.10
Traditionally, only variants achieving genome-wide signiﬁcance for
phenotype A are tested in phenotype B in the proxy-phenotype method.
Here we show that a substantial genetic signal is found among variants
that have less signiﬁcant P-values of association and take the novel
approach to test all variants that make up the most predictive PRS for PBC
for association with MS, including variants that do not reach genome-wide
signiﬁcance for PBC.
Variance explained
The variance explained by previously identiﬁed and newly identiﬁed
variants and HLA alleles was calculated using the formula:
R2 ¼
X
i2A β
2
i ´ fi ´ 1 fið Þ; (3)
where β is the log of the OR estimate for the variant and f is the frequency
of the effect allele.
To estimate the variance explained by HLA alleles, we used the HLA
alleles listed in Table 1 of a recent study of HLA alleles in MS.31 To facilitate
comparison with the variants outside the MHC region, all of which were
identiﬁed through an additive model of association, we used only those
alleles reported to associate with MS in an additive model. In this way, our
estimates are conservative.
Annotation
We looked for overlap of our newly identiﬁed loci with other ADs by
performing a literary search and by looking them up in Immunobase, a
webpage containing most or all risk loci for ADs, available at http://www.
immunobase.org/.
We performed an eQTL analysis in whole blood as previously
described.19 Brieﬂy, microarray hybridization assay was carried out on
RNA isolated from blood of 1002 individuals and the expression intensities
were adjusted for (age, neutrophil count, lymphocyte count, monocyte
count)*sex. The P-values of association were generated by testing if the
slope of the linear regression between expression and genotype was
different from 0. These data are referred to as the deCODE in-house eQTL
data. We also explored the effect of the variants on expression in data from
the genotype expression trait (GTEx) project.18 As stated in the text, we
only link the associated variant with changes in expression when it is either
itself the variant most strongly associating with expression in the locus, or
highly correlated (r2 > 0.94) with the variant most strongly associating with
expression in both data sets.
To determine if the variants overlapped TFBS we used the open
regulatory annotation database (ORegAnno), which contains information on
experimentally identiﬁed TFBS.20 To look for DNase I hypersensitivity clusters
and regions with speciﬁc histone modiﬁcations, we used data from the
ENCyclopedia of DNA elements (ENCODE) project.21 Although the precise
mechanism by which histone modiﬁcation regulates gene expression
remains to be worked out, some patterns have emerged from recent
research. These include that high levels of H3K4Me1 (single methylation on
lysine residue number four of histone 3) but low levels of H3K4Me3 are
indicative of an enhancer element while high H3K4Me3 characterizes
promoter regions.77 Similarly, acetylation of lysine residue number 27 of
histone 3 (H3K27ac) has been found to discriminate between active and
inactive enhancer regions.78 We restricted our analysis to the seven cell lines
included in the ﬁrst phase of the ENCODE project but all results presented in
this paper are from GM12878, which is a lymphoblastoid cell line and out of
the seven, likely represents the most relevant cell type for the study of ADs.
In our interpretation of these data, we are aware that although histone
modiﬁcation in promoters is relatively similar across cell types, the
modiﬁcation patterns in enhancers are often cell-type-speciﬁc.79 Therefore,
even if our variants are found in regions that have histone modiﬁcation
pattern indicative of enhancer in GM12878, it is by no means certain that
this is also the case in other cell types that might be more relevant in MS.
Data availability
Summary statistics for ADs used to derive PRSs and, in the case of MS,
included in a meta-analysis, are available at https://www.immunobase.org/
and https://www.ibdgenetics.org/. Other data are available from the
corresponding authors upon reasonable request.
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